KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Return on Sales (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Return on Sales for 9 consecutive years, with 0.6% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 81.0% year-over-year to 0.6%, compared with a TTM value of 0.3% through Dec 2025, up 50.0%, and an annual FY2025 reading of 0.3%, up 50.0% over the prior year.
  • Return on Sales was 0.6% for Q4 2025 at Biocryst Pharmaceuticals, up from 0.08% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.6% in Q4 2025 and bottomed at 0.59% in Q4 2023.
  • Average Return on Sales over 3 years is 0.13%, with a median of 0.14% recorded in 2023.
  • The sharpest move saw Return on Sales dropped -2bps in 2024, then skyrocketed 81bps in 2025.
  • Year by year, Return on Sales stood at 0.59% in 2023, then surged by 66bps to 0.2% in 2024, then skyrocketed by 397bps to 0.6% in 2025.
  • Business Quant data shows Return on Sales for BCRX at 0.6% in Q4 2025, 0.08% in Q3 2025, and 0.03% in Q2 2025.